Table 1:

Clinical characteristics, procedural details and survival impact^a of the patient cohort

	Patient cohort		OS impact
	n	%	HR (95% CI)	P-value
Age
<65	52	51	1.02 (1.00–1.04)/year	0.034
>65	49	49	–	–
Gender
Male	54	53	0.89 (0.59–1.33)	0.57
Female	47	47	1	–
Malignancy
Lung cancer	62	61	1.00 (0.66–1.51)	0.99
Others	39	39	1	–
Treatment intent
Palliative	93	92	1	–
Curative	8	8	0.12 (0.04–0.34)	<0.001
Oncological treatment
None	26	26	1	–
Prior	38	38	0.55 (0.33–0.92)	0.022
After	21	21	0.31 (0.17–0.58)	<0.001
Both	16	16	0.48 (0.25–0.89)	0.021
Urgency
Non-urgent	22	22	1	–
Semi-urgent	61	60	0.85 (0.51–1.40)	0.52
Urgent	18	18	1.73 (0.92–3.28)	0.09
Procedure type
Stent only	62	61	1	–
Stent + laser	34	34	0.60 (0.39–0.93)	0.021
Stent + dilation	5	5	0.40 (0.14–1.10)	0.076
Site
Upper trachea	18	18	1	–
Lower trachea	17	17	1.49 (0.74–3.00)	0.26
Carina	10	10	2.16 (0.95–4.91)	0.065
Right main bronchus	23	23	1.66 (0.87–3.16)	0.12
Left main bronchus	31	31	1.36 (0.74–2.49)	0.33
Both main bronchi	2	2	2.53 (0.57–12.24)	0.22
Stent type
Coated	75	74	1	–
Non-coated	11	11	0.78 (0.40–1.52)	0.47
No data	15	15	–	–

^aImpact of each variable on OS was tested in a univariable analysis using Cox proportional hazards model. HRs with 95% CIs are reported.

CI: confidence interval; HR: hazard ratio; OS: overall survival.